Florida’s Cannabis Renewal Bill Is $1.34 Million. Fino Has One Store

When Joe Puglise’s Fino Cannabis announced its first Florida dispensary in June 2026, it gave the venture a precise address: 833 State Road 50 in Clermont. The pitch emphasized patient education and conversation in a setting intended to feel hospitable. It was the public-facing end of a larger undertaking. Florida requires a medical marijuana treatment center to secure authorization for cultivation, processing and dispensing before it can sell to patients. (S1, S2)

By the state’s September 4 report, Fino still had one dispensing location. Trulieve had 170. Both operated inside a licensing system whose published renewal schedule sets a two-year fee of $1,340,383.11 for renewal applications due in 2025 and 2026. The schedule charges at the treatment-center license level, rather than posting a separate price for each store. Its uneven weight across a large chain and a new entrant is the business problem. (S2, S3)

That comparison does not establish Fino’s next due date or say the company is delinquent. It identifies the fixed renewal charge facing licenses in the published period. A company with one store and a company with many stores have different amounts of operating activity across which to spread that expense. (S2, S3)

The newest constraint arrived in an August 24 proposal from the Office of Medical Marijuana Use. Proposed Rule 64-4.227 would define permitted advertising channels and content, prohibit celebrity and influencer marketing, and restrict exterior signage. The notice’s comment period runs through September 14. For a company trying to establish a new name, the draft reaches the means of finding customers as well as the words used to describe its products. (S4, S5)

The numbers do not support a simple story in which every Florida operator is retreating. The September 4 state report lists 779 dispensing locations and 941,509 qualified patients with active identification cards. It also identifies a newly approved Curaleaf location in Riverview. Those are measures of access points and program enrollment. They are not statewide sales revenue, unique weekly shoppers or evidence that each new location earns enough to cover its costs. (S2)

Fino recorded 43.102 ounces of smokable marijuana dispensed in the week from August 28 through September 3. That small entry establishes that the company is participating in the market. It cannot be multiplied by a guessed shelf price to produce a reliable revenue figure: the public report does not provide product mix, discounts or actual receipts. (S2)

Puglise explained the attraction in a July interview with MJBizDaily. A limited number of licenses, the ability to add stores and a large patient base made Florida appealing to him. He also argued that Fino’s lack of legacy debt gave it flexibility. They nevertheless explain why he chose to enter a market other businesses find difficult. (S6)

Fino’s route also distinguishes it from applicants still waiting for a newly issued permit. MJBizDaily traced its license to the acquisition of Planet 13 Florida in May 2024. Planet 13’s own closing announcement says it sold all the equity in that subsidiary for US$9 million, following state approval. That is a historical transaction price for a particular business, not a current valuation for every Florida license and not a measure of what a new store alone costs. (S6, S7)

The renewal charge has a statutory rationale. Florida law directs the health department to set initial and biennial renewal fees sufficient to cover specified program costs. It also requires financial capacity for the two-year approval cycle. This puts part of the regulatory system’s financing on the licensed operators. The disagreement is therefore about how the costs are allocated and what they do to entry and survival, rather than whether the department invented a fee without legislative authority. (S8)

Sanctuary Cannabis challenged the sharp increase in renewal fees. In March 2025, Florida’s First District Court of Appeal rejected arguments that other marijuana-related revenue should offset those charges, as reported by MJBizDaily. Chief Judge Timothy Osterhaus described the formula as consistent with the costs specified by statute. That history explains why an operator cannot treat industry objections to the fee as evidence that the obligation has been suspended. (S9)

The published 2025-2026 schedule is more precise than the shorthand used in many reports: $1,340,383.11 for the two-year period. Divided evenly over 24 months, that is about $55,849 a month. This is an editorial cost comparison, not a state installment plan. (S3)

“Most dispensaries are built around transactions.”

— Joe Puglise, chief executive officer, Fino Cannabis; June 2026 company announcement (S1)

Puglise’s answer is to make the store experience distinguish Fino. Its June announcement described staff guidance, terpene education and a planned second location in Winter Park. A business built around education still has to persuade patients to find the first storefront. (S1)

Florida already restricts public-facing medical cannabis advertising. Section 381.986 limits what can be visible from streets and other public places, provides for identifying signage, and sets conditions on internet marketing. It bars content appealing to children or promoting recreational use. The draft would add more detailed definitions and operating rules inside a market that was never an unrestricted advertising environment. (S8)

The proposal defines a celebrity by both public recognition and an agreement, obligation or economic incentive to promote a treatment center or its products. It similarly covers influencers and even computer-generated characters with social followings. It would prohibit advertising that depicts or uses those figures, along with content suggesting cures, promoting recreational consumption or appealing to children. (S5)

Signage would be limited to one exterior or window sign, with specified identifying content and limits on placement and illumination. The draft also says advertising inside a dispensary must not be visible to the public outside. For a shop in a retail plaza, those details can affect how easily someone recognizes the premises and which existing materials can stay. The actual cost would depend on the location, its present signs and the final adopted language. (S5)

The social-media provision contains a distinction worth preserving. A treatment center would need department approval for its social-media accounts, but would not need advance approval before each ordinary post on its own approved accounts. Such posts would still be confined to permitted content, including contact details, store locations, hours, products and prices. Describing the draft as a requirement to submit every post for approval would misstate the text. (S5)

Sponsored or paid internet advertisements would require prior approval under the referenced advertising rule. The draft also limits the platforms and audience-selection practices a treatment center may use. The result is a different process for a paid campaign than for an ordinary post on an approved account. For a small company, that distinction can affect the staff time needed to plan a promotion even when the promotional message itself is permitted. (S5)

Tallahassee attorney John Lockwood told Politico he had requested a public meeting on the proposed restrictions and expected the industry to seek changes. His concern was the cost of altering practices developed over years of operating under existing law. Puglise, speaking to the same publication, worried about attracting patients as a startup. Those are operator-side objections. The proposal’s prohibitions on misleading claims, child appeal and recreational promotion set out the public-protection side of the dispute. (S5, S10)

The state’s restrictions and the companies’ commercial concerns can both be read directly. A medical program has a reason to police unsupported health claims and marketing aimed at children. An established operator or new entrant also has a reason to ask whether a particular sign or approved-account post creates that risk. The rulemaking process is where those arguments can be tested against the actual language, rather than collapsed into an argument for or against all cannabis advertising. (S5, S8)

Parallel’s July closures show the other end of the investment cycle. Cannabis Business Times reported that the parent of Surterra Wellness closed cultivation and processing facilities in Wimauma and Lakeland, affecting 211 employees. In the company’s notice, head of people and culture Robin DeBaise described the employment losses and closures as permanent. The report divided the affected jobs between 157 in Wimauma and 54 in Lakeland. (S11)

Those facilities came from an earlier expansion strategy. In March 2020, Innovative Industrial Properties announced it bought the Wimauma property for $35.3 million and leased it back to a Parallel subsidiary. IIP President and Chief Executive Officer Paul Smithers described the property as supporting growth; Parallel’s then-chairman and chief executive, Beau Wrigley, described the transaction as a source of expansion capital. Both statements reflected expectations at the time of that deal. (S12)

A sale-leaseback provides capital while creating continuing occupancy obligations. That economic structure helps explain why a cultivation property can remain financially consequential long after the growth plan behind it changes. It does not establish that the lease caused Parallel’s closures. The available closure reporting does not support attributing all 211 job losses to one fee, one proposed rule or one financing arrangement. (S11, S12)

Surterra still appears with 44 dispensing locations in the September 4 state report. Closing two production facilities is therefore different from shutting the entire retail brand. That distinction belongs alongside the expanding statewide location count: Florida can record new stores while a particular operator contracts elsewhere in its operation. The market contains both kinds of decision, and the public figures should not be made to tell only one of them. (S2, S11)

Back in Clermont, Puglise’s plan depends on making a first store useful enough that patients return. The state’s report confirms a small operating foothold. The renewal schedule describes a much larger fixed obligation, and the proposed advertising rule could narrow how the company introduces itself. Fino entered Florida for the opportunity created by a limited-license market. Its next test is how much of that opportunity one storefront can pay for. (S1, S2, S3, S5)

Keep Reading

Market Data

GAO Finds Cannabis Banking’s Gap: An Account Doesn’t Mean Full Access

Federal investigators heard from 74 financial institutions and 51 cannabis businesses. Their report describes costly accounts, restricted credit and fragile payment services, while warning that its roughly 1,000 reporting institutions are not a directory of banks accepting dispensaries.

By Cannabis Inc, Editorial Staff·8 min read

Market Data

Connecticut Collected 67% More Cannabis Tax on Flat Sales. The Math Behind It Dies Oct. 1

The state's per-milligram THC tax kept climbing as shelf prices fell 40%, pushing effective rates to 35% on some products. A flat 10.75% excise replaces it Oct. 1, at a projected cost to the state of $1.9 million a year, and operators like Fine Fettle's Ben Zachs say it can't come soon enough.

By Cannabis Inc, Editorial Staff·7 min read